These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10933174)

  • 1. Questionable long-term benefit of mycophenolate.
    Steiner RW
    Transplantation; 2000 Jul; 70(2):401. PubMed ID: 10933174
    [No Abstract]   [Full Text] [Related]  

  • 2. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
    Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract]   [Full Text] [Related]  

  • 3. Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.
    Crespo JF; Górriz JL; Sancho A; Avila A; Alcoy E; Pallardó LM
    Transplant Proc; 1999 Sep; 31(6):2261-2. PubMed ID: 10500568
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term experience with mycofenolate mofetil in the prevention of renal allograft rejection.
    Behrend M; Lueck R; Pichlmayr R
    Transplant Proc; 1997 Nov; 29(7):2927-9. PubMed ID: 9365617
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
    Sells RA; Bakran A; Brown MW; Grinyo J; Hammad A; Hyatt D; Owens G
    Transplant Proc; 1998 Dec; 30(8):4098. PubMed ID: 9865311
    [No Abstract]   [Full Text] [Related]  

  • 6. Triple therapy with mycophenolate mofetil versus azathioprine.
    Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
    Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
    [No Abstract]   [Full Text] [Related]  

  • 7. Tolerance of mycophenolate mofetil is dependent on kidney function.
    Puggia R; Rizzolo M; Maresca MC; Calconi G; Vianello A
    Transplant Proc; 1998 Aug; 30(5):2228. PubMed ID: 9723450
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of mycophenolate mofetil on the prevention of acute renal allograft rejection.
    Miladipour AH; Ghods AJ; Nejadgashti H
    Transplant Proc; 2002 Sep; 34(6):2089-90. PubMed ID: 12270325
    [No Abstract]   [Full Text] [Related]  

  • 9. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
    Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.
    Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S; Chiewsilp P; Leenanupunth C; Kochakarn W
    Transplant Proc; 1998 Nov; 30(7):3576-7. PubMed ID: 9838566
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term benefit of mycophenolate mofetil in renal transplantation.
    Lang P; Pardon A; Audard V
    Transplantation; 2005 Feb; 79(3 Suppl):S47-8. PubMed ID: 15699751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil in ongoing chronic kidney allograft dysfunction.
    Senn B; Rochat P; Schwarzkopf AK; Weinreich T; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4075-6. PubMed ID: 9865301
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil in living donor renal allograft recipients.
    Park K; Moon JI; Kim SI; Kim YS
    Transplant Proc; 1999; 31(1-2):1133. PubMed ID: 10083506
    [No Abstract]   [Full Text] [Related]  

  • 15. Mofetil mycophenolate in renal transplantation.
    Pretagostini R; Rossi M; Berloco P; Colonnello M; Bruzzone P; Peritore D; Lonardo MT; Cortesini R
    Transplant Proc; 2001; 33(1-2):1082-3. PubMed ID: 11267200
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycophenolate mofetil reduces late renal allograft loss: a 4-year study.
    Nghiem DD; Gignac MR; Marcus RD; Hsia S; Schlosser JD
    Transplant Proc; 2002 Aug; 34(5):1683-4. PubMed ID: 12176534
    [No Abstract]   [Full Text] [Related]  

  • 17. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation.
    Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Grewal HP; Siegel CT; Pellar S; Josephson MA; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1538-40. PubMed ID: 9636625
    [No Abstract]   [Full Text] [Related]  

  • 18. The Tricontinental Mycophenolate Mofetil Trial.
    Browne BJ
    Transplantation; 1996 Dec; 62(11):1697. PubMed ID: 8970635
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil.
    Sola E; Alférez MJ; Cabello M; Burgos D; González Molina M
    Transplant Proc; 2002 Aug; 34(5):1689-90. PubMed ID: 12176537
    [No Abstract]   [Full Text] [Related]  

  • 20. Lymphocyte subsets in renal transplant recipients treated with mycophenolate mofetil.
    François M; Büchler M; Halimi JM; Al-Najjar A; Valentin JF; Thibault G; Lebranchu Y
    Transplant Proc; 2000 Dec; 32(8):2781-2. PubMed ID: 11134803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.